Long-term adalimumab therapy in patients with nonradiographic axial spondyloarthritis provides sustained clinical and functional improvements with no additional safety issues. The three-year, open label extension of the ABILITY-1 trial found ‘similar and sustained’ improvements in the Ankylosing Spondylitis Disease Activity Score (ASDAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). This was consistent in ...
TNFi effective in nonradiographic axial SpA
By Mardi Chapman
4 Apr 2018